- Lucid Diagnostics (LUCD, Financial) to hold a business update conference call and webcast on May 14, 2025.
- CEO Lishan Aklog and CFO Dennis McGrath will present an update on operations and Q1 2025 financials.
- The webcast will be available online with a 30-day replay option.
Lucid Diagnostics Inc. (LUCD), a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. (PAVM), has announced a business update conference call and webcast scheduled for May 14, 2025, at 8:30 AM ET. The conference will feature presentations from Chairman and CEO Lishan Aklog, M.D., and CFO Dennis McGrath. They will discuss the company's operations, growth strategy, and review financial results for the first quarter of 2025.
Investors and interested parties in the U.S. can join the call by dialing 1-800-836-8184, while international participants should use 1-646-357-8785. Participants are advised to reference "Lucid Diagnostics Business Update" when joining. The webcast will be accessible through the investor relations section of Lucid's website at luciddx.com. A replay of the webcast will remain available for 30 days following the call.
Lucid Diagnostics is dedicated to early cancer detection, focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of esophageal precancer and cancer. The company offers the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, pioneering commercially available tools for early detection and cancer prevention.
For further information, visit Lucid Diagnostics' website or their parent company PAVmed at pavmed.com.
